Urologie pro praxi 4/2019
Benign prostatic hyperplasia – latest pharmacotherapy options, risks and limitations of treatment
Benign prostatic hyperplasia (BPH) presents one of the most frequent condition among middle-aged and elderly men. Even though its benign biological potential, symptoms of BPH can have negative impact on patient’s quality of life and cause chronic or acute complications. Properly chosen pharmacotherapy represents an effective way to reduce patient’s complaints and minimize the risk of complications or need of surgical intervention.
Keywords: benign prostatic hyperplasia, lower urinary tract symptoms, alpha1-blockers, 5alfa-reductase inhibitors, phosphodiesterase 5 inhibitors, muscarinic receptor antagonists, beta-3 agonists, combination therapy.
